Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic options. We performed a systematic review an...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonerba, Carlo, Dolce, Pasquale, Iaccarino, Simona, Scafuri, Luca, Verde, Antonio, Costabile, Ferdinando, Pagliuca, Martina, Morra, Rocco, Riccio, Vittorio, Ribera, Dario, De Placido, Pietro, Romeo, Valeria, Crocetto, Felice, Longo, Nicola, Imbimbo, Ciro, De Placido, Sabino, Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072485/
https://www.ncbi.nlm.nih.gov/pubmed/32050629
http://dx.doi.org/10.3390/cancers12020408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072485/
https://www.ncbi.nlm.nih.gov/pubmed/32050629
http://dx.doi.org/10.3390/cancers12020408

Ejemplares similares